The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October ...

Ionis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide margins. The profit surge in Q2 2025 included a ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

In eukaryotic cells, the nucleolus is the central site for ribosome biogenesis. It is composed of distinct subcompartments: fibrillar center (FC), dense fibrillar component (DFC), periphery of DFC ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Adrian R. Krainer has been awarded the 2025 Heinrich Wieland Prize for his pioneering RNA research that led to the ...

Scientists at Johns Hopkins have discovered how a natural RNA molecule can block HIV from reactivating, opening doors to a ...

We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized ...

SAN FRANCISCO, CA, USA I July 21, 2025 I AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology ...

Data supports further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma.

Clinical data from the OT‑101 P001 PDAC study suggest that targeting TGFB2 merits additional evaluation in younger patients; ...